ERBB2 and breast cancer: In terms of molecular subtype, HER2+ (80.1%) and TN (75.5%) BC patients were more likely (vs. HR+/HER2−, 35.3%) to receive adjuvant chemotherapy (HER2+: OR = 12.67, 95% CI = 8.77–18.52; TN, OR = 6.67, 95% CI = 4.67–9.52; P<0.001).